Stock Analysis on Net
Stock Analysis on Net

Gilead Sciences Inc. (NASDAQ:GILD)

Analysis of Short-term (Operating) Activity Ratios
Quarterly Data

Beginner level


Short-term Activity Ratios (Summary)

Gilead Sciences Inc., short-term (operating) activity ratios (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Turnover Ratios
Inventory turnover 4.52 4.75 5.07 5.17 5.22 5.36 5.96 5.56 5.22 4.99 5.46 3.66 3.04 2.73 2.68 2.24 2.25 2.30 2.05
Receivables turnover 6.84 5.73 6.18 6.64 6.46 6.66 6.52 6.30 6.43 6.43 6.66 6.56 6.26 7.10 6.64 6.14 5.55 5.26 5.49
Payables turnover 8.93 7.94 6.56 7.22 7.48 8.33 6.14 7.83 7.20 6.21 5.37 6.02 5.23 4.26 3.53 4.04 3.73 4.57 3.40
Working capital turnover 1.55 1.24 1.08 1.17 0.89 0.89 0.86 0.88 1.04 1.24 1.27 1.05 1.40 2.18 2.67 3.01 4.04 3.88 2.16
Average No. Days
Average inventory processing period 81 77 72 71 70 68 61 66 70 73 67 100 120 134 136 163 162 159 178
Add: Average receivable collection period 53 64 59 55 56 55 56 58 57 57 55 56 58 51 55 59 66 69 66
Operating cycle 134 141 131 126 126 123 117 124 127 130 122 156 178 185 191 222 228 228 244
Less: Average payables payment period 41 46 56 51 49 44 59 47 51 59 68 61 70 86 103 90 98 80 107
Cash conversion cycle 93 95 75 75 77 79 58 77 76 71 54 95 108 99 88 132 130 148 137

Based on: 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08).

Short-term activity ratio Description The company
Inventory turnover An activity ratio calculated as cost of goods sold divided by inventory. Gilead Sciences Inc.’s inventory turnover ratio deteriorated from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.
Receivables turnover An activity ratio equal to revenue divided by receivables. Gilead Sciences Inc.’s receivables turnover ratio deteriorated from Q4 2019 to Q1 2020 but then improved from Q1 2020 to Q2 2020 exceeding Q4 2019 level.
Payables turnover An activity ratio calculated as cost of goods sold divided by payables. Gilead Sciences Inc.’s payables turnover ratio increased from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.
Working capital turnover An activity ratio calculated as revenue divided by working capital. Gilead Sciences Inc.’s working capital turnover ratio improved from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.

Short-term activity ratio Description The company
Average inventory processing period An activity ratio equal to the number of days in the period divided by inventory turnover over the period. Gilead Sciences Inc.’s number of days of inventory outstanding deteriorated from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.
Average receivable collection period An activity ratio equal to the number of days in the period divided by receivables turnover. Gilead Sciences Inc.’s number of days of receivables outstanding deteriorated from Q4 2019 to Q1 2020 but then improved from Q1 2020 to Q2 2020 exceeding Q4 2019 level.
Operating cycle Equal to average inventory processing period plus average receivables collection period. Gilead Sciences Inc.’s operating cycle deteriorated from Q4 2019 to Q1 2020 but then improved from Q1 2020 to Q2 2020 not reaching Q4 2019 level.
Average payables payment period An estimate of the average number of days it takes a company to pay its suppliers; equal to the number of days in the period divided by payables turnover ratio for the period. Gilead Sciences Inc.’s number of days of payables outstanding decreased from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.
Cash conversion cycle A financial metric that measures the length of time required for a company to convert cash invested in its operations to cash received as a result of its operations; equal to average inventory processing period plus average receivables collection period minus average payables payment period. Gilead Sciences Inc.’s cash conversion cycle deteriorated from Q4 2019 to Q1 2020 but then slightly improved from Q1 2020 to Q2 2020.

Inventory Turnover

Gilead Sciences Inc., inventory turnover calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data (US$ in millions)
Cost of goods sold 1,064  969  1,683  1,035  1,000  957  1,570  1,086  1,196  1,001  1,256  1,032  1,126  957  1,075  1,129  864  1,193  1,062  1,064  998  882 
Inventories 1,052  986  922  882  884  898  814  816  859  885  801  1,144  1,408  1,474  1,587  1,900  1,862  1,880  1,955  1,988  2,039  1,908 
Short-term Activity Ratio
Inventory turnover1 4.52 4.75 5.07 5.17 5.22 5.36 5.96 5.56 5.22 4.99 5.46 3.66 3.04 2.73 2.68 2.24 2.25 2.30 2.05
Benchmarks
Inventory Turnover, Competitors2
Abbott Laboratories 2.56 2.92 3.07 2.96 2.94 3.13 3.35 3.38 3.36 3.23 3.43 3.27 3.00 2.49 3.71 3.41 3.15 3.16 3.37
AbbVie Inc. 2.36 4.17 4.10 3.86 3.89 4.40 4.81 4.47 4.91 4.23 4.39 3.54 3.92 4.26 4.04 3.53 3.08 2.75 2.62
Amgen Inc. 1.38 1.31 1.22 1.29 1.32 1.40 1.39 1.35 1.31 1.36 1.44 1.39 1.39 1.44 1.52 1.55 1.56 1.64 1.74
Biogen Inc. 1.83 2.10 2.43 2.66 2.61 2.56 1.95 2.00 1.87 1.90 1.81 1.49 1.65 1.68 1.48 1.42 1.33 1.29 1.39
Bristol-Myers Squibb Co. 4.45 3.49 1.88 6.15 5.48 5.31 5.48 5.09 5.20 5.19 5.20 4.62 4.53 3.72 3.99 3.05 3.00 3.08 3.20
Eli Lilly & Co. 1.48 1.55 1.48 1.62 1.70 1.96 1.56 1.57 1.56 1.36 1.36 1.34 1.32 1.40 1.59 1.44 1.44 1.38 1.46
Illumina Inc. 2.29 2.74 3.00 2.55 2.53 2.55 2.68 2.65 2.67 2.69 2.78 2.72 2.71 2.63 2.44 2.28 2.23 2.37 2.48
Johnson & Johnson 2.93 3.16 3.05 2.99 2.93 2.98 3.15 3.15 3.14 2.95 2.89 2.48 2.29 2.45 2.66 2.57 2.53 2.64 2.67
Merck & Co. Inc. 2.33 2.46 2.36 2.35 2.29 2.34 2.48 2.52 2.56 2.41 2.51 2.41 2.37 2.59 2.85 2.75 2.81 2.93 3.18
Pfizer Inc. 1.15 1.21 1.23 1.30 1.31 1.38 1.50 1.40 1.43 1.39 1.48 1.41 1.51 1.61 1.82 1.67 1.53 1.41 1.28
Regeneron Pharmaceuticals Inc. 0.25 0.25 0.26 0.22 0.16 0.15 0.16 0.18 0.22 0.26 0.28 0.30 0.32 0.38 0.49 0.64 0.82 0.92 1.01
Vertex Pharmaceuticals Inc. 3.03 3.29 3.27 2.99 3.25 3.17 3.29 2.99 2.89 2.55 2.46 2.56 2.52 2.52 2.71 2.97 2.87 2.58 2.18
Zoetis Inc. 1.21 1.31 1.41 1.39 1.42 1.46 1.37 1.27 1.26 1.23 1.24 1.20 1.18 1.12 1.11 1.08 1.12 1.19 1.18

Based on: 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08).

1 Q2 2020 Calculation
Inventory turnover = (Cost of goods soldQ2 2020 + Cost of goods soldQ1 2020 + Cost of goods soldQ4 2019 + Cost of goods soldQ3 2019) ÷ Inventories
= (1,064 + 969 + 1,683 + 1,035) ÷ 1,052 = 4.52

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Inventory turnover An activity ratio calculated as cost of goods sold divided by inventory. Gilead Sciences Inc.’s inventory turnover ratio deteriorated from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.

Receivables Turnover

Gilead Sciences Inc., receivables turnover calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data (US$ in millions)
Product sales 5,067  5,467  5,796  5,516  5,607  5,200  5,681  5,455  5,540  5,001  5,837  6,402  7,046  6,377  7,216  7,405  7,651  7,681  8,409  8,211  8,126  7,405 
Accounts receivable, net of allowances 3,194  3,907  3,582  3,315  3,396  3,283  3,327  3,465  3,541  3,775  3,851  4,122  4,478  4,034  4,514  5,075  5,752  6,163  5,854  6,105  5,331  4,835 
Short-term Activity Ratio
Receivables turnover1 6.84 5.73 6.18 6.64 6.46 6.66 6.52 6.30 6.43 6.43 6.66 6.56 6.26 7.10 6.64 6.14 5.55 5.26 5.49
Benchmarks
Receivables Turnover, Competitors2
Abbott Laboratories 6.12 6.06 5.88 5.75 5.58 5.75 5.90 5.77 5.70 5.31 5.22 5.24 5.10 4.95 6.42 6.24 5.76 5.95 5.97
AbbVie Inc. 4.34 5.35 6.13 5.94 5.95 5.75 6.08 5.57 5.34 5.07 5.55 5.58 5.50 5.61 5.39 5.05 4.90 5.00 4.83
Amgen Inc. 4.31 4.55 5.47 6.19 5.89 5.96 6.29 6.42 6.29 6.04 6.73 6.43 6.17 6.73 6.92 6.77 7.00 6.92 6.99
Biogen Inc. 5.40 5.55 6.05 5.83 5.70 5.29 5.56 5.34 5.44 5.41 5.79 6.47 6.17 6.59 6.81 6.64 7.42 6.68 7.49
Eli Lilly & Co. 4.75 4.52 4.91 5.10 5.04 5.70 4.68 5.00 4.95 5.19 5.03 5.11 5.06 5.37 5.27 5.41 5.22 5.57 5.68
Illumina Inc. 8.70 7.53 6.18 6.39 7.24 7.43 6.48 7.49 7.86 7.34 6.70 6.77 6.68 6.59 6.29 6.21 6.21 5.60 5.76
Johnson & Johnson 5.50 5.56 5.67 5.52 5.55 5.78 5.79 5.79 5.72 5.56 5.67 5.65 5.46 5.87 6.14 6.07 5.88 6.15 6.53
Merck & Co. Inc. 6.23 5.88 6.91 5.45 5.57 5.66 5.98 5.66 5.66 5.62 5.84 5.19 5.38 5.65 5.67 5.42 5.70 5.75 6.09
Pfizer Inc. 5.39 5.13 5.93 5.62 5.48 5.61 6.68 5.32 5.39 5.57 6.39 5.25 5.52 5.92 6.42 5.41 5.72 5.65 5.97
Regeneron Pharmaceuticals Inc. 2.51 2.41 2.30 2.29 2.31 2.44 2.38 2.39 2.56 2.51 2.42 2.35 2.47 2.55 2.49 2.42 2.17 2.02 2.33
Vertex Pharmaceuticals Inc. 6.82 5.70 6.57 8.16 7.43 7.45 7.44 7.45 6.67 7.38 8.85 8.71 8.60 9.71 8.47 9.12 8.22 7.10 5.81
Zoetis Inc. 6.44 6.57 5.76 5.97 6.08 6.10 5.62 6.16 5.74 5.77 5.32 5.08 5.15 5.20 5.35 5.34 5.47 5.31 5.09

Based on: 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08).

1 Q2 2020 Calculation
Receivables turnover = (Product salesQ2 2020 + Product salesQ1 2020 + Product salesQ4 2019 + Product salesQ3 2019) ÷ Accounts receivable, net of allowances
= (5,067 + 5,467 + 5,796 + 5,516) ÷ 3,194 = 6.84

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Receivables turnover An activity ratio equal to revenue divided by receivables. Gilead Sciences Inc.’s receivables turnover ratio deteriorated from Q4 2019 to Q1 2020 but then improved from Q1 2020 to Q2 2020 exceeding Q4 2019 level.

Payables Turnover

Gilead Sciences Inc., payables turnover calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data (US$ in millions)
Cost of goods sold 1,064  969  1,683  1,035  1,000  957  1,570  1,086  1,196  1,001  1,256  1,032  1,126  957  1,075  1,129  864  1,193  1,062  1,064  998  882 
Accounts payable 532  590  713  632  617  577  790  580  623  711  814  696  819  944  1,206  1,052  1,122  945  1,178  1,239  1,571  1,011 
Short-term Activity Ratio
Payables turnover1 8.93 7.94 6.56 7.22 7.48 8.33 6.14 7.83 7.20 6.21 5.37 6.02 5.23 4.26 3.53 4.04 3.73 4.57 3.40
Benchmarks
Payables Turnover, Competitors2
Abbott Laboratories 4.00 4.20 4.07 4.29 3.97 4.20 4.27 4.68 4.98 4.99 5.14 6.13 6.49 6.70 7.66 8.49 7.70 8.36 8.09
Amgen Inc. 4.60 3.60 3.18 4.18 4.20 3.86 3.40 3.90 3.92 3.69 3.01 4.64 4.66 4.59 4.54 5.05 4.80 5.15 4.38
Biogen Inc. 4.54 4.65 3.68 5.22 5.38 5.22 4.90 5.37 5.91 4.89 4.12 5.02 4.68 4.90 5.28 5.23 5.87 4.57 4.64
Bristol-Myers Squibb Co. 3.72 3.22 3.30 3.89 3.58 3.44 3.46 3.68 3.45 3.70 2.70 3.40 3.55 3.43 2.97 3.21 2.86 2.67 2.50
Eli Lilly & Co. 3.92 3.97 3.36 4.51 4.52 5.13 4.55 5.04 4.91 4.98 4.30 4.93 4.57 4.64 4.19 4.80 4.48 4.49 3.76
Illumina Inc. 7.36 8.11 7.22 7.44 7.63 7.67 5.61 6.35 6.49 6.23 5.79 5.63 4.79 5.54 5.31 5.32 2.77 4.41 4.82
Johnson & Johnson 4.09 3.78 3.23 3.66 3.92 3.91 3.59 3.91 4.25 4.13 3.47 3.70 3.62 3.57 3.13 3.65 3.56 3.62 3.23
Merck & Co. Inc. 4.10 4.02 3.78 4.29 4.25 4.43 4.07 4.41 4.39 4.09 4.12 4.85 4.37 5.37 4.95 5.81 5.87 6.67 5.90
Pfizer Inc. 2.55 2.56 2.42 2.71 2.69 2.68 2.41 2.66 2.76 2.92 2.41 3.22 3.33 3.52 2.72 3.60 3.57 3.41 2.67
Regeneron Pharmaceuticals Inc. 1.07 1.06 0.87 0.89 0.87 0.76 0.82 1.10 1.19 1.01 1.14
Vertex Pharmaceuticals Inc. 6.54 6.11 6.25 5.24 6.03 5.26 3.69 4.03 4.01 4.05 3.72 3.26 3.06 3.27 3.42 4.19 3.73 2.17 1.66
Zoetis Inc. 5.73 7.29 6.62 7.06 6.90 8.43 6.11 7.66 7.77 8.20 6.80 8.38 8.85 7.45 6.29 7.03 7.61 8.25 5.93

Based on: 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08).

1 Q2 2020 Calculation
Payables turnover = (Cost of goods soldQ2 2020 + Cost of goods soldQ1 2020 + Cost of goods soldQ4 2019 + Cost of goods soldQ3 2019) ÷ Accounts payable
= (1,064 + 969 + 1,683 + 1,035) ÷ 532 = 8.93

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Payables turnover An activity ratio calculated as cost of goods sold divided by payables. Gilead Sciences Inc.’s payables turnover ratio increased from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.

Working Capital Turnover

Gilead Sciences Inc., working capital turnover calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data (US$ in millions)
Current assets 24,643  26,950  30,296  28,361  33,727  34,024  35,836  34,918  32,728  30,258  31,823  35,317  28,592  21,424  20,445  21,425  18,353  19,267  24,763  25,910  18,093  20,062 
Less: Current liabilities 10,564  8,879  9,759  9,567  8,961  9,397  10,605  10,116  10,912  10,670  11,635  9,597  8,492  8,282  9,219  11,073  10,444  10,910  9,891  9,360  8,925  7,428 
Working capital 14,079  18,071  20,537  18,794  24,766  24,627  25,231  24,802  21,816  19,588  20,188  25,720  20,100  13,142  11,226  10,352  7,909  8,357  14,872  16,550  9,168  12,634 
 
Product sales 5,067  5,467  5,796  5,516  5,607  5,200  5,681  5,455  5,540  5,001  5,837  6,402  7,046  6,377  7,216  7,405  7,651  7,681  8,409  8,211  8,126  7,405 
Short-term Activity Ratio
Working capital turnover1 1.55 1.24 1.08 1.17 0.89 0.89 0.86 0.88 1.04 1.24 1.27 1.05 1.40 2.18 2.67 3.01 4.04 3.88 2.16
Benchmarks
Working Capital Turnover, Competitors2
Abbott Laboratories 5.02 6.84 6.64 5.57 5.04 5.80 5.44 5.61 5.72 4.78 2.44 1.87 1.79 1.76 1.04 4.45 4.76 5.08 4.11
AbbVie Inc. 0.97 0.98 12.30 64.14 10.46 8.75 6.16 4.62 5.68 3.91 4.00 3.51 3.29 3.99 4.22
Amgen Inc. 1.87 3.27 3.96 1.10 1.11 1.00 0.93 0.85 0.82 0.73 0.54 0.53 0.54 0.61 0.63 0.61 0.67 0.63 0.70
Biogen Inc. 2.28 3.44 3.23 2.81 2.38 1.91 2.51 1.94 2.48 1.49 2.30 2.46 2.70 2.56 1.85 1.74 1.95 2.11 2.23
Bristol-Myers Squibb Co. 3.09 2.38 2.28 0.78 0.82 2.71 3.32 4.04 5.09 3.91 3.64 3.39 3.52 3.58 3.64 3.98 3.58 4.13 5.86
Eli Lilly & Co. 8.85 16.68 11.54 12.35 14.53 17.59 2.84 2.46 4.52 4.95 4.90 4.72 4.94 8.54 5.16 4.08 4.50 4.61 4.59
Illumina Inc. 1.09 1.09 0.94 0.96 0.96 1.03 1.24 1.28 1.46 1.46 1.23 1.21 1.27 1.35 1.49 1.44 1.48 1.41 1.49
Johnson & Johnson 8.83 7.85 8.81 8.91 7.79 6.34 5.51 4.12 4.49 5.02 6.09 7.42 7.31 1.89 1.86 1.79 1.58 1.73 2.16
Merck & Co. Inc. 6.59 17.87 8.90 8.42 10.53 6.33 11.53 5.06 6.95 5.72 6.52 4.71 4.25 3.41 2.97 2.87 3.03 3.52 3.74
Pfizer Inc. 3.59 59.74 3.57 3.39 2.97 4.25 10.34 7.05 4.90 4.35 5.69 4.78 6.74 14.23 4.45 4.06 3.39
Regeneron Pharmaceuticals Inc. 1.20 0.75 0.86 0.87 0.90 0.78 0.82 0.93 1.13 1.17 1.16 1.20 1.24 1.45 1.72 1.27 1.38 1.32 1.28
Vertex Pharmaceuticals Inc. 1.10 1.23 1.19 1.07 1.00 1.06 1.12 1.05 1.06 1.09 1.35 1.42 1.37 1.46 1.64 2.13 1.87 1.52 1.15
Zoetis Inc. 1.42 2.08 2.13 1.72 1.77 1.79 1.83 1.86 1.71 1.67 1.70 1.63 2.79 3.00 2.15 2.10 2.12 2.25 2.33

Based on: 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08).

1 Q2 2020 Calculation
Working capital turnover = (Product salesQ2 2020 + Product salesQ1 2020 + Product salesQ4 2019 + Product salesQ3 2019) ÷ Working capital
= (5,067 + 5,467 + 5,796 + 5,516) ÷ 14,079 = 1.55

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Working capital turnover An activity ratio calculated as revenue divided by working capital. Gilead Sciences Inc.’s working capital turnover ratio improved from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.

Average Inventory Processing Period

Gilead Sciences Inc., average inventory processing period calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data
Inventory turnover 4.52 4.75 5.07 5.17 5.22 5.36 5.96 5.56 5.22 4.99 5.46 3.66 3.04 2.73 2.68 2.24 2.25 2.30 2.05
Short-term Activity Ratio (no. days)
Average inventory processing period1 81 77 72 71 70 68 61 66 70 73 67 100 120 134 136 163 162 159 178
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
Abbott Laboratories 142 125 119 123 124 116 109 108 109 113 107 112 122 147 98 107 116 115 108
AbbVie Inc. 155 88 89 94 94 83 76 82 74 86 83 103 93 86 90 103 118 133 139
Amgen Inc. 265 279 300 282 276 261 262 271 278 268 254 262 263 253 241 235 234 223 210
Biogen Inc. 200 173 150 137 140 143 187 182 195 192 202 245 221 217 247 257 274 284 263
Bristol-Myers Squibb Co. 82 105 194 59 67 69 67 72 70 70 70 79 81 98 92 120 122 119 114
Eli Lilly & Co. 247 236 247 225 214 186 233 233 235 268 268 272 276 260 230 254 253 264 250
Illumina Inc. 160 133 122 143 144 143 136 138 137 136 131 134 134 139 150 160 164 154 147
Johnson & Johnson 124 116 119 122 125 122 116 116 116 124 126 147 159 149 137 142 144 138 136
Merck & Co. Inc. 156 148 155 156 160 156 147 145 142 152 146 151 154 141 128 133 130 125 115
Pfizer Inc. 317 302 296 281 279 264 244 261 254 262 246 258 242 227 201 219 238 259 284
Regeneron Pharmaceuticals Inc. 1,476 1,460 1,426 1,648 2,260 2,429 2,334 2,011 1,659 1,423 1,309 1,205 1,138 963 749 570 446 398 360
Vertex Pharmaceuticals Inc. 121 111 112 122 112 115 111 122 126 143 148 142 145 145 135 123 127 142 168
Zoetis Inc. 301 280 258 262 256 251 266 288 290 296 293 305 310 326 329 337 326 308 308

Based on: 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08).

1 Q2 2020 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 4.52 = 81

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Average inventory processing period An activity ratio equal to the number of days in the period divided by inventory turnover over the period. Gilead Sciences Inc.’s number of days of inventory outstanding deteriorated from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.

Average Receivable Collection Period

Gilead Sciences Inc., average receivable collection period calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data
Receivables turnover 6.84 5.73 6.18 6.64 6.46 6.66 6.52 6.30 6.43 6.43 6.66 6.56 6.26 7.10 6.64 6.14 5.55 5.26 5.49
Short-term Activity Ratio (no. days)
Average receivable collection period1 53 64 59 55 56 55 56 58 57 57 55 56 58 51 55 59 66 69 66
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
Abbott Laboratories 60 60 62 63 65 64 62 63 64 69 70 70 72 74 57 59 63 61 61
AbbVie Inc. 84 68 60 61 61 64 60 66 68 72 66 65 66 65 68 72 74 73 76
Amgen Inc. 85 80 67 59 62 61 58 57 58 60 54 57 59 54 53 54 52 53 52
Biogen Inc. 68 66 60 63 64 69 66 68 67 67 63 56 59 55 54 55 49 55 49
Eli Lilly & Co. 77 81 74 72 72 64 78 73 74 70 73 71 72 68 69 67 70 66 64
Illumina Inc. 42 48 59 57 50 49 56 49 46 50 55 54 55 55 58 59 59 65 63
Johnson & Johnson 66 66 64 66 66 63 63 63 64 66 64 65 67 62 59 60 62 59 56
Merck & Co. Inc. 59 62 53 67 66 64 61 64 64 65 63 70 68 65 64 67 64 63 60
Pfizer Inc. 68 71 62 65 67 65 55 69 68 65 57 70 66 62 57 67 64 65 61
Regeneron Pharmaceuticals Inc. 146 152 159 159 158 149 153 152 143 145 151 155 148 143 147 151 168 181 156
Vertex Pharmaceuticals Inc. 53 64 56 45 49 49 49 49 55 49 41 42 42 38 43 40 44 51 63
Zoetis Inc. 57 56 63 61 60 60 65 59 64 63 69 72 71 70 68 68 67 69 72

Based on: 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08).

1 Q2 2020 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 6.84 = 53

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Average receivable collection period An activity ratio equal to the number of days in the period divided by receivables turnover. Gilead Sciences Inc.’s number of days of receivables outstanding deteriorated from Q4 2019 to Q1 2020 but then improved from Q1 2020 to Q2 2020 exceeding Q4 2019 level.

Operating Cycle

Gilead Sciences Inc., operating cycle calculation (quarterly data)

No. days

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data
Average inventory processing period 81 77 72 71 70 68 61 66 70 73 67 100 120 134 136 163 162 159 178
Average receivable collection period 53 64 59 55 56 55 56 58 57 57 55 56 58 51 55 59 66 69 66
Short-term Activity Ratio
Operating cycle1 134 141 131 126 126 123 117 124 127 130 122 156 178 185 191 222 228 228 244
Benchmarks
Operating Cycle, Competitors2
Abbott Laboratories 202 185 181 186 189 180 171 171 173 182 177 182 194 221 155 166 179 176 169
AbbVie Inc. 239 156 149 155 155 147 136 148 142 158 149 168 159 151 158 175 192 206 215
Amgen Inc. 350 359 367 341 338 322 320 328 336 328 308 319 322 307 294 289 286 276 262
Biogen Inc. 268 239 210 200 204 212 253 250 262 259 265 301 280 272 301 312 323 339 312
Eli Lilly & Co. 324 317 321 297 286 250 311 306 309 338 341 343 348 328 299 321 323 330 314
Illumina Inc. 202 181 181 200 194 192 192 187 183 186 186 188 189 194 208 219 223 219 210
Johnson & Johnson 190 182 183 188 191 185 179 179 180 190 190 212 226 211 196 202 206 197 192
Merck & Co. Inc. 215 210 208 223 226 220 208 209 206 217 209 221 222 206 192 200 194 188 175
Pfizer Inc. 385 373 358 346 346 329 299 330 322 327 303 328 308 289 258 286 302 324 345
Regeneron Pharmaceuticals Inc. 1,622 1,612 1,585 1,807 2,418 2,578 2,487 2,163 1,802 1,568 1,460 1,360 1,286 1,106 896 721 614 579 516
Vertex Pharmaceuticals Inc. 174 175 168 167 161 164 160 171 181 192 189 184 187 183 178 163 171 193 231
Zoetis Inc. 358 336 321 323 316 311 331 347 354 359 362 377 381 396 397 405 393 377 380

Based on: 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08).

1 Q2 2020 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 81 + 53 = 134

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Operating cycle Equal to average inventory processing period plus average receivables collection period. Gilead Sciences Inc.’s operating cycle deteriorated from Q4 2019 to Q1 2020 but then improved from Q1 2020 to Q2 2020 not reaching Q4 2019 level.

Average Payables Payment Period

Gilead Sciences Inc., average payables payment period calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data
Payables turnover 8.93 7.94 6.56 7.22 7.48 8.33 6.14 7.83 7.20 6.21 5.37 6.02 5.23 4.26 3.53 4.04 3.73 4.57 3.40
Short-term Activity Ratio (no. days)
Average payables payment period1 41 46 56 51 49 44 59 47 51 59 68 61 70 86 103 90 98 80 107
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
Abbott Laboratories 91 87 90 85 92 87 85 78 73 73 71 60 56 54 48 43 47 44 45
Amgen Inc. 79 101 115 87 87 95 107 94 93 99 121 79 78 80 80 72 76 71 83
Biogen Inc. 80 79 99 70 68 70 74 68 62 75 89 73 78 74 69 70 62 80 79
Bristol-Myers Squibb Co. 98 113 110 94 102 106 105 99 106 99 135 107 103 106 123 114 127 137 146
Eli Lilly & Co. 93 92 109 81 81 71 80 72 74 73 85 74 80 79 87 76 81 81 97
Illumina Inc. 50 45 51 49 48 48 65 57 56 59 63 65 76 66 69 69 132 83 76
Johnson & Johnson 89 97 113 100 93 93 102 93 86 88 105 99 101 102 116 100 103 101 113
Merck & Co. Inc. 89 91 97 85 86 82 90 83 83 89 89 75 83 68 74 63 62 55 62
Pfizer Inc. 143 143 151 135 136 136 152 137 132 125 151 113 110 104 134 101 102 107 137
Regeneron Pharmaceuticals Inc. 342 343 421 411 419 481 442 333 307 360 321
Vertex Pharmaceuticals Inc. 56 60 58 70 61 69 99 91 91 90 98 112 119 111 107 87 98 169 220
Zoetis Inc. 64 50 55 52 53 43 60 48 47 45 54 44 41 49 58 52 48 44 62

Based on: 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08).

1 Q2 2020 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 8.93 = 41

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Average payables payment period An estimate of the average number of days it takes a company to pay its suppliers; equal to the number of days in the period divided by payables turnover ratio for the period. Gilead Sciences Inc.’s number of days of payables outstanding decreased from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.

Cash Conversion Cycle

Gilead Sciences Inc., cash conversion cycle calculation (quarterly data)

No. days

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data
Average inventory processing period 81 77 72 71 70 68 61 66 70 73 67 100 120 134 136 163 162 159 178
Average receivable collection period 53 64 59 55 56 55 56 58 57 57 55 56 58 51 55 59 66 69 66
Average payables payment period 41 46 56 51 49 44 59 47 51 59 68 61 70 86 103 90 98 80 107
Short-term Activity Ratio
Cash conversion cycle1 93 95 75 75 77 79 58 77 76 71 54 95 108 99 88 132 130 148 137
Benchmarks
Cash Conversion Cycle, Competitors2
Abbott Laboratories 111 98 91 101 97 93 86 93 100 109 106 122 138 167 107 123 132 132 124
Amgen Inc. 271 258 252 254 251 227 213 234 243 229 187 240 244 227 214 217 210 205 179
Biogen Inc. 188 160 111 130 136 142 179 182 200 184 176 228 202 198 232 242 261 259 233
Eli Lilly & Co. 231 225 212 216 205 179 231 234 235 265 256 269 268 249 212 245 242 249 217
Illumina Inc. 152 136 130 151 146 144 127 130 127 127 123 123 113 128 139 150 91 136 134
Johnson & Johnson 101 85 70 88 98 92 77 86 94 102 85 113 125 109 80 102 103 96 79
Merck & Co. Inc. 126 119 111 138 140 138 118 126 123 128 120 146 139 138 118 137 132 133 113
Pfizer Inc. 242 230 207 211 210 193 147 193 190 202 152 215 198 185 124 185 200 217 208
Regeneron Pharmaceuticals Inc. 1,280 1,269 1,164 1,396 1,999 2,097 2,045 1,830 1,495 1,208 1,139
Vertex Pharmaceuticals Inc. 118 115 110 97 100 95 61 80 90 102 91 72 68 72 71 76 73 24 11
Zoetis Inc. 294 286 266 271 263 268 271 299 307 314 308 333 340 347 339 353 345 333 318

Based on: 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08).

1 Q2 2020 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 81 + 5341 = 93

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Cash conversion cycle A financial metric that measures the length of time required for a company to convert cash invested in its operations to cash received as a result of its operations; equal to average inventory processing period plus average receivables collection period minus average payables payment period. Gilead Sciences Inc.’s cash conversion cycle deteriorated from Q4 2019 to Q1 2020 but then slightly improved from Q1 2020 to Q2 2020.